Table 2.
Summary of mean (SD) noncompartmental pharmacokinetic parameters for ICA-105665 by treatment groupa
| Dose, mg (N) | Cmax, ng/ml | Tmax, h | Half-life, h |
|---|---|---|---|
| 100 (4) | 3,318 (873) | 2.20 (0.73) | 4.26 (0.91) |
| 200 (4) | 6,228 (2,073) | 3.38 (1.23) | 4.03 (0.81) |
| 400 (4) | 10,738 (3,856) | 2.68 (1.44) | 4.67 (1.90) |
| 500 (6) | 13,902 (3,932) | 4.70 (1.91) | 8.28 (4.04) |
| 600 (1) | 14,700 | 6.50 | 5.81 |
a
Four subjects participated in more than one dose group. Subject 101, a female in the 100-mg dose group, was reenrolled as subject 105 in the 200-mg dose group. Subject 102, a male in the 100-mg dose group was reenrolled as subject 107 in the 200-mg dose group, and 108 in the 400-mg dose group. Subject 104, a male in the 100-mg dose group, was reenrolled as subject 106 in the 200-mg dose group and subject 109 in the 400 mg dose group. Subject 301 in the 200-mg dose group was reenrolled as subject 302 in the 400-mg dose group.